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Background: Clopidogrel has provided beneficial effects in acute coronary syn-
dromes and percutaneous coronary intervention. Different polymorphisms have
been associated with differences in clopidogrel response. The aim of this study
was to check if CYP2C19/ABCB1-genotype–guided strategy reduces the rates of
cardiovascular events.
Methods: Experimental study included patients undergoing percutaneous coro-
nary intervention with stent. The prospective genotype–guided strategy (interven-
tion group) was compared against a restrospective non-tailored strategy (control
group). Primary efficacy endpoint was the composite of cardiovascular death,
acute coronary syndrome or stroke during 12 months after intervention. Sec-
ondary end-point was to compare the efficacy of the different antiplatelet ther-
apies used in genotyping conditions.
Results: The study included a total of 719 patients undergone stent, more than
86% with acute coronary syndrome. The primary end-point occurred in 32 pa-
tients (10.1%) in the genotyping group and in 59 patients (14.1%) in the control
group (HR 0.63, 95% CI 0.41 - 0.97, p=0.037). There was no difference in TIMI
major and minor bleeding between the two groups (4.1% vs. 4.7%, HR 0.80, 95%
CI 0.39- 1.63, p 0.55). In intervention group, there was no difference in the rate of
events in patients treated with clopidogrel versus patients treated with other anti-
platelet treatments (9.1% vs 11.5% p=0.44), or bleeding (3.7% vs 4.6%, p=0.69).
Primary end-point and other variables
End-point Intervention group Control group HR (95% CI) p-value
(n=317) (n=402)
CV death, ACS, stroke 32 (10.1%) 59 (14.1%) 0.63 (0.41–0.97) 0.037
CV death 2 (0.6%) 12 (3%) 0.19 (0.04–0.86) 0.03
ACS 27 (8.5%) 41 (10.2%) 0.71 (0.47–1.26) 0.31
Stroke 2 (0.6%) 8 (2%) 0.32 (0.07–1.49) 0.12
Non CV death 2 (0.6%) 1 (0.2%) 2.41 (0.21–26.5) 0.47
Urgent revascularization
not related with ST 12 (3.8%) 22 (5.5%) 0.63 (0.31–1.28) 0.20
ST 1 (0.3%) 1 (0.2%) 1.27 (0.08–20.2) 0.87
CV: cardiovascular; ACS: acute coronary syndrome; ST: stent thrombosis; HR: Hazard ratio.
Kaplan–Meier survival and Cox model
Conclusion: Our results demonstrate that genotype–guided strategy reduces the
rates of composite of cardiovascular death, acute coronary syndrome or stroke
during 12 months after percutaneous coronary intervention compared to a non-
genotype-guide strategy.
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Purpose: Antiaggregation therapy is still the most frequently used approach to
prevent thrombotic events in cardiovascular diseases. It has a good clinical ef-
fect but increasing evidence shows high residual platelet aggregation activity in a
number of patients. Laboratory methods only allow us to detect clopidogrel “non-
responders” or “low responders”. Recent methods are based on monitoring resid-
ual platelet aggregation activity (aggregation methods) or detecting the number
of free epitopes for binding a specific monoclonal antibody such as vasodilator-
stimulated phosphoprotein phosphorylation (VASP).
Methods: The aims of our study were comparison light transmission aggregom-
etry (LTA) and multiple electrode platelet aggregometry (MEA) with induction by
ADP in concentrations of 20 micromol/L with or without prostaglandin E1 (PGE1)
for monitoring clopidogrel resistance.
Results: In the group of 84 patients with cardiovascular disease (CAD) stud-
ied, an impaired individual response to clopidogrel therapy was found 11.9% and
10.7% of the patients using MEA and LTA, respectively, induced by ADP with
PGE1. The LTA and MEA methods with induction by ADP with PGE1 and without
PGE1 were statistically compared using Spearman’s nonparametric correlation
analysis. Both methods with using PGE, showed a positive significant correlation
(p=0.003) in contrast with the results without PGE1 with a no significant correla-
tion (p=0.732).
Conclusions: The sensitivity for detecting clopidogrel resistance correlates well
with other data in the literature suggesting that there are 5%-30% clopidogrel low-
responders depending on the type of platelet function assay used and the criteria
for defining a low-responder. These results favor implementation of the ADP test
with PGE1 by MEA specifically for identification of low-responders to clopidogrel.
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Introduction: European Society of Cardiology has been providing guidelines for
the diagnostic and therapeutic approach of many cardiovascular diseases. It is
important to understand whether actual guidance is based on robust evidence
in the current evidence-based medicine era. Therefore we aimed to describe the
current scenario of recommendations in ESC cardiovascular guidelines and the
distribution of levels of evidence across recommendations.
Methods: Data from current disease-based ESC practice guidelines were scruti-
nized. Guidelines evaluating procedures across conditions (e.g. myocardial revas-
cularization) were not included. The number of recommendations and the distri-
bution of classes of recommendation (I, II, and III) and levels of evidence (A, B,
and C) were determined.
Results: Considering the 21 current disease-based guidelines reporting levels
of evidence, there were 2621 recommendations. About 13.8% were classified as
level of evidence A, whereas 57% of the recommendations were level of evidence
C. Class I recommendations (1309) were substantially based on level of evidence
C (49.5%), while level of evidence A supported 20.5% of these recommendations.
Class III recommendations (198, 7.5% of all recommendations) relied mostly on
level of evidence C (56.1% of class III recommendations). Nevertheless, level of
evidence A recommendations were often used to provide class I recommenda-
tions.
Conclusions: Recommendations issued in current ESC disease-based guide-
lines are largely developed from lower levels of evidence or expert opinion. The







/eurheartj/article-abstract/37/suppl_1/599/2197552 by Faculdade de M
edicina de Lisboa user on 02 N
ovem
ber 2018
